Exicure (XCUR) Competitors $4.17 -0.01 (-0.24%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$4.18 +0.01 (+0.24%) As of 10/3/2025 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XCUR vs. TCRX, ABOS, IRD, CGTX, ANEB, ATRA, IPA, ALXO, ADVM, and COYAShould you be buying Exicure stock or one of its competitors? The main competitors of Exicure include TScan Therapeutics (TCRX), Acumen Pharmaceuticals (ABOS), Opus Genetics (IRD), Cognition Therapeutics (CGTX), Anebulo Pharmaceuticals (ANEB), Atara Biotherapeutics (ATRA), ImmunoPrecise Antibodies (IPA), ALX Oncology (ALXO), Adverum Biotechnologies (ADVM), and Coya Therapeutics (COYA). These companies are all part of the "pharmaceutical products" industry. Exicure vs. Its Competitors TScan Therapeutics Acumen Pharmaceuticals Opus Genetics Cognition Therapeutics Anebulo Pharmaceuticals Atara Biotherapeutics ImmunoPrecise Antibodies ALX Oncology Adverum Biotechnologies Coya Therapeutics Exicure (NASDAQ:XCUR) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership. Does the media prefer XCUR or TCRX? In the previous week, Exicure's average media sentiment score of 0.00 equaled TScan Therapeutics'average media sentiment score. Company Overall Sentiment Exicure Neutral TScan Therapeutics Neutral Do institutionals & insiders have more ownership in XCUR or TCRX? 42.8% of Exicure shares are owned by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are owned by institutional investors. 52.8% of Exicure shares are owned by company insiders. Comparatively, 4.4% of TScan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has preferable earnings and valuation, XCUR or TCRX? Exicure has higher earnings, but lower revenue than TScan Therapeutics. TScan Therapeutics is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExicure$500K52.71-$9.70M-$3.88-1.07TScan Therapeutics$6.96M17.20-$127.50M-$1.09-1.94 Do analysts recommend XCUR or TCRX? TScan Therapeutics has a consensus target price of $7.80, indicating a potential upside of 269.67%. Given TScan Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe TScan Therapeutics is more favorable than Exicure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00TScan Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Is XCUR or TCRX more profitable? Exicure has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,964.88%. TScan Therapeutics' return on equity of -63.33% beat Exicure's return on equity.Company Net Margins Return on Equity Return on Assets ExicureN/A -192.16% -84.30% TScan Therapeutics -1,964.88%-63.33%-40.19% Which has more volatility & risk, XCUR or TCRX? Exicure has a beta of 3.76, meaning that its stock price is 276% more volatile than the S&P 500. Comparatively, TScan Therapeutics has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500. SummaryTScan Therapeutics beats Exicure on 8 of the 14 factors compared between the two stocks. Get Exicure News Delivered to You Automatically Sign up to receive the latest news and ratings for XCUR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XCUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XCUR vs. The Competition Export to ExcelMetricExicureMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$26.34M$3.36B$6.13B$10.58BDividend YieldN/A2.28%5.66%4.69%P/E Ratio-1.077.9365.2722.75Price / Sales52.71459.60607.74132.59Price / CashN/A46.3226.3031.09Price / Book3.729.9012.536.57Net Income-$9.70M-$52.45M$3.30B$276.78M7 Day Performance9.45%5.22%4.28%2.42%1 Month Performance-12.21%10.61%6.90%8.63%1 Year Performance54.44%25.03%70.54%31.60% Exicure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XCURExicure1.1835 of 5 stars$4.17-0.2%N/A+54.4%$26.34M$500K-1.0750Gap UpTCRXTScan Therapeutics1.9751 of 5 stars$1.79+2.6%$7.80+337.0%-61.7%$101.30M$2.82M-1.64100ABOSAcumen Pharmaceuticals3.2289 of 5 stars$1.65+4.4%$7.00+324.2%-27.0%$99.94MN/A-0.7220News CoveragePositive NewsHigh Trading VolumeIRDOpus Genetics2.2127 of 5 stars$1.65-8.1%$7.33+345.8%N/A$99.45M$10.99M-0.8614Short Interest ↑CGTXCognition Therapeutics2.6707 of 5 stars$1.35-5.9%$2.83+110.7%+256.3%$98.89MN/A-2.0120ANEBAnebulo Pharmaceuticals2.8827 of 5 stars$2.40-0.8%$5.50+129.2%+21.6%$98.59MN/A-9.234Earnings ReportATRAAtara Biotherapeutics4.5813 of 5 stars$13.87+0.4%$21.00+51.4%+87.4%$97.38M$188.67M-32.25330News CoverageIPAImmunoPrecise Antibodies1.1135 of 5 stars$2.10+8.5%$4.00+90.9%+235.2%$96.68M$17.59M-3.0880Positive NewsGap UpALXOALX Oncology3.6589 of 5 stars$1.80+2.6%$3.30+83.8%+29.8%$96.12MN/A-0.8240News CoverageADVMAdverum Biotechnologies3.9645 of 5 stars$4.51-2.0%$19.75+338.3%-28.4%$94.49M$1M-0.57190News CoverageGap DownCOYACoya Therapeutics2.7025 of 5 stars$5.63-0.5%$16.20+187.7%-16.0%$94.16M$423.45K-4.546Analyst Forecast Related Companies and Tools Related Companies TScan Therapeutics Alternatives Acumen Pharmaceuticals Alternatives Opus Genetics Alternatives Cognition Therapeutics Alternatives Anebulo Pharmaceuticals Alternatives Atara Biotherapeutics Alternatives ImmunoPrecise Antibodies Alternatives ALX Oncology Alternatives Adverum Biotechnologies Alternatives Coya Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XCUR) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exicure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exicure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XCUR Stock Alerts